1. ¹Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
2. ²Department of Radiology, Washington University School of Medicine, St Louis, MO, USA
3. ³Department of Neurology, Washington University School of Medicine, St Louis, MO, USA
4. ⁴Department of Psychology, Washington University School of Medicine, St Louis, MO, USA
5. ⁵Department of Medicine, Washington University School of Medicine, St Louis, MO, USA

Correspondence: Dr YI Sheline, Department of Psychiatry, Box 8134, Washington University School of Medicine, 660 S Euclid Ave., St Louis, MO 63110, USA. Tel: +314 362 8422; Fax: +314 362 7599; E-mail: yvette@npg.wustl.edu

Received 5 December 2003; Revised 18 March 2004; Accepted 19 March 2004; Published online 15 September 2004.

Abstract

Serotonin receptor changes have been associated with the pathophysiology and treatment of major depression. Only one other study has investigated serotonin receptor changes in older depressed patients. We used positron emission tomography (PET) and [¹⁸F]altanserin, a ligand with high affinity for the 5-HT_2A receptor, to examine the relationship between 5-HT_2A receptor density and depression. Depressed subjects (n=16), age>50 years, were recruited as part of a larger study. Older depressed subjects consisted of early-onset recurrent depression (EORD, n=11) and late-onset depression (LOD, n=5). An age-matched control group (n=9) was also recruited. All subjects were right-handed, nonsmokers and antidepressant-free. Regions of interest were determined on a summed MPRAGE scan transformed into Talairach space and coregistered with the PET images. Depressed subjects had less hippocampal 5-HT_2A receptor binding than controls (p=0.05). No significant differences in receptor binding were found between EORD and LOD subjects. Depressed subjects not previously treated for depression (n=6) had less hippocampal 5-HT_2A receptor binding (p=0.04) than previously treated subjects (n=10). It may be that prior medication treatment provides a compensatory upregulation of the 5-HT_2A receptor.